SCHEMBL7236286

SCHEMBL7236286

COc1c(OC)c(OC)c2c(=O)c3cccc(OC)c3oc2c1OC

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOA P21397 11/20 0.68
ALDH1A1 P00352 3/20 0.57
KDM4E B2RXH2 2/20 0.57
LMNA P02545 2/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 1/20 0.57
ABCB1 P08183 1/20 0.50
ABCG2 Q9UNQ0 1/20 0.50
HPGD P15428 2/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
MGAM O43451 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18240048 0.89 MAOA (0.67) MAOAALDH1A1KDM4ELMNANPC1
SCHEMBL7230998 0.83 MAOA (0.58) MAOAALDH1A1KDM4EABCB1ABCG2
SCHEMBL27918534 0.82 MGAM (0.70) MAOAALDH1A1KDM4ELMNANPC1
SCHEMBL27714097 0.82 MAOA (0.70) MAOAALDH1A1KDM4ELMNANPC1
SCHEMBL27876462 0.78 MAOA (0.60) MAOAALDH1A1KDM4ELMNANPC1
SCHEMBL10127076 0.76 MAOA (0.59) MAOAALDH1A1KDM4ELMNANPC1
SCHEMBL775094 0.75 ABCG2 (0.60) MAOAALDH1A1KDM4ENPC1ABCB1
SCHEMBL38655958 0.75 MAOA (0.84) MAOAALDH1A1KDM4ELMNANPC1
SCHEMBL18240045 0.75 MAOA (0.84) MAOAALDH1A1KDM4ELMNANPC1
SCHEMBL29365851 0.75 MAOA (0.84) MAOAALDH1A1KDM4ELMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104936626-A Coating for substrate GORE & ASS 2015-09-23 CN disclosed
CN-102526215-A Extraction technology for removing polygala tenuifolia toxic substances and keeping anti-depressant effective components LEI WANG 2012-07-04 CN disclosed
US-6613797-B2 New xanthone derivatives useful for treating protozoan diseases INTERLAB, INC. 2003-09-02 US disclosed
EP-0888052-A4 XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES INTERLAB CORP (US) 2002-05-22 EP disclosed
US-20020055644-A1 Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins INTERLAB, INC. 2002-05-09 US disclosed
WO-2001041773-A1 XANTHONE ANALOGS FOR TREATING INFECTIOUS DISEASES AND COMPLEXATION OF HEME AND PORPHYRINS INTERLAB, INC. (US) 2001-06-14 WO disclosed
US-5977077-A PARASITICIDES; ANTIPROTOZOA AGENT INTERLAB CORPORATION (US) 1999-11-02 US disclosed
EP-0888052-A1 XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES INTERLAB CORPORATION (US) 1999-01-07 EP disclosed
WO-1997034482-A1 XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES INTERLAB CORP. (US) 1997-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055644-A1 Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins XPA, XDH, HMOX1 MAOA 680/4885ALDH1A1 4117/4885KDM4E 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.